Literature DB >> 11704759

Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome.

M Tartaglia1, E L Mehler, R Goldberg, G Zampino, H G Brunner, H Kremer, I van der Burgt, A H Crosby, A Ion, S Jeffery, K Kalidas, M A Patton, R S Kucherlapati, B D Gelb.   

Abstract

Noonan syndrome (MIM 163950) is an autosomal dominant disorder characterized by dysmorphic facial features, proportionate short stature and heart disease (most commonly pulmonic stenosis and hypertrophic cardiomyopathy). Webbed neck, chest deformity, cryptorchidism, mental retardation and bleeding diatheses also are frequently associated with this disease. This syndrome is relatively common, with an estimated incidence of 1 in 1,000-2,500 live births. It has been mapped to a 5-cM region (NS1) [corrected] on chromosome 12q24.1, and genetic heterogeneity has also been documented. Here we show that missense mutations in PTPN11 (MIM 176876)-a gene encoding the nonreceptor protein tyrosine phosphatase SHP-2, which contains two Src homology 2 (SH2) domains-cause Noonan syndrome and account for more than 50% of the cases that we examined. All PTPN11 missense mutations cluster in interacting portions of the amino N-SH2 domain and the phosphotyrosine phosphatase domains, which are involved in switching the protein between its inactive and active conformations. An energetics-based structural analysis of two N-SH2 mutants indicates that in these mutants there may be a significant shift of the equilibrium favoring the active conformation. This implies that they are gain-of-function changes and that the pathogenesis of Noonan syndrome arises from excessive SHP-2 activity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11704759     DOI: 10.1038/ng772

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  476 in total

1.  Finding genetic contributions to sporadic disease: a recessive locus at 12q24 commonly contributes to patent ductus arteriosus.

Authors:  Arya Mani; Seyed-Mahmoud Meraji; Roozbeh Houshyar; Jayaram Radhakrishnan; Alaleh Mani; Mehrabeh Ahangar; Tayebeh M Rezaie; Mohammad-Ali Taghavinejad; Behrooz Broumand; Hongyu Zhao; Carol Nelson-Williams; Richard P Lifton
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-30       Impact factor: 11.205

2.  G-CSF receptor activation of the Src kinase Lyn is mediated by Gab2 recruitment of the Shp2 phosphatase.

Authors:  Muneyoshi Futami; Quan-Sheng Zhu; Zakary L Whichard; Ling Xia; Yuehai Ke; Benjamin G Neel; Gen-Sheng Feng; Seth J Corey
Journal:  Blood       Date:  2011-06-02       Impact factor: 22.113

3.  Noonan syndrome with leukaemoid reaction and overproduction of catecholamines: a case report.

Authors:  Tatsuro Kondoh; Eiich Ishii; Yoko Aoki; Takashi Shimizu; Masafumi Zaitsu; Yoichi Matsubara; Hiroyuki Moriuchi
Journal:  Eur J Pediatr       Date:  2003-05-09       Impact factor: 3.183

4.  Key issues in the computational simulation of GPCR function: representation of loop domains.

Authors:  E L Mehler; X Periole; S A Hassan; H Weinstein
Journal:  J Comput Aided Mol Des       Date:  2002-11       Impact factor: 3.686

5.  SHP-2 positively regulates myogenesis by coupling to the Rho GTPase signaling pathway.

Authors:  Maria I Kontaridis; Seda Eminaga; Mara Fornaro; Christina Ivins Zito; Raffaella Sordella; Jeffrey Settleman; Anton M Bennett
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

6.  Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.

Authors:  Gordon Chan; Demetrios Kalaitzidis; Tatiana Usenko; Jeffery L Kutok; Wentian Yang; M Golam Mohi; Benjamin G Neel
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

7.  Cardiomyopathies in Noonan syndrome and the other RASopathies.

Authors:  Bruce D Gelb; Amy E Roberts; Marco Tartaglia
Journal:  Prog Pediatr Cardiol       Date:  2015-07-01

8.  Genotype differences in cognitive functioning in Noonan syndrome.

Authors:  E I Pierpont; M E Pierpont; N J Mendelsohn; A E Roberts; E Tworog-Dube; M S Seidenberg
Journal:  Genes Brain Behav       Date:  2008-12-11       Impact factor: 3.449

9.  Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner.

Authors:  Hong Zheng; Wen-Mei Yu; Ronald R Waclaw; Maria I Kontaridis; Benjamin G Neel; Cheng-Kui Qu
Journal:  Sci Signal       Date:  2018-03-20       Impact factor: 8.192

10.  Shp2-dependent ERK signaling is essential for induction of Bergmann glia and foliation of the cerebellum.

Authors:  Kairong Li; Alan W Leung; Qiuxia Guo; Wentian Yang; James Y H Li
Journal:  J Neurosci       Date:  2014-01-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.